Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Biolife ApS

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 5.8% 5.8% 5.8% 5.8% 1.5% 5.8% 5.8%   Bankruptcy risk   13.3% 19.7% 12.9% 15.8% 13.5% 12.4% 14.7% 14.4%   Credit score (0-100)   18 7 18 11 16 14 2 3   Credit rating   B C B B B B B B   Credit limit (kDKK)   0.0 -0.0 0.0 -0.0 -0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 -191 0 0 0 0 0 0   Gross profit   44.1 -49.4 50.2 -37.3 -6.0 16.3 0.0 0.0   EBITDA   44.1 -49.4 26.2 -37.3 -6.0 16.3 0.0 0.0   EBIT   44.1 -49.4 26.2 -37.3 -6.0 16.3 0.0 0.0   Pre-tax profit (PTP)   44.1 -50.3 25.2 -37.4 -6.0 16.0 0.0 0.0   Net earnings   44.1 -50.3 25.2 -43.1 -6.0 17.8 0.0 0.0   Pre-tax profit without non-rec. items   44.1 -50.3 25.2 -37.4 -6.0 16.0 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   44.1 -6.2 19.1 -3.1 -9.2 8.7 -31.3 -31.3   Interest-bearing liabilities   0.0 57.0 0.0 24.7 44.0 10.7 31.3 31.3   Balance sheet total (assets)   95.8 96.5 52.8 46.7 102 80.5 0.0 0.0   Net Debt   -10.1 39.6 -15.7 22.2 38.1 -7.2 31.3 31.3     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 -191 0 0 0 0 0 0   Net sales growth   0.0% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   44.1 -49.4 50.2 -37.3 -6.0 16.3 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 0.0% 83.9% 0.0% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   96 96 53 47 102 81 0 0   Balance sheet change%   0.0% 0.8% -45.3% -11.5% 118.4% -21.0% -100.0% 0.0%   Added value   44.1 -49.4 26.2 -37.3 -6.0 16.3 0.0 0.0   Added value %   0.0% 25.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 -1.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 -1.0 1.0 -1.0 -2.0 1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 25.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 52.2% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 26.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 26.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 26.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   46.1% -49.8% 33.7% -72.7% -7.5% 17.1% 0.0% 0.0%   ROI %   100.0% -97.7% 68.9% -170.3% -17.5% 51.5% 0.0% 0.0%   ROE %   100.0% -71.6% 43.7% -131.1% -8.1% 32.2% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   46.1% -6.0% 36.1% -6.2% -8.2% 10.8% -100.0% -100.0%   Relative indebtedness %   0.0% -53.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% -44.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -22.8% -80.2% -60.0% -59.5% -634.1% -44.2% 0.0% 0.0%   Gearing %   0.0% -920.5% 0.0% -795.8% -481.1% 124.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 3.2% 3.3% 0.7% 0.1% 1.2% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.9 0.9 1.6 0.9 0.9 1.1 0.0 0.0   Current Ratio   1.9 0.9 1.6 0.9 0.9 1.1 0.0 0.0   Cash and cash equivalent   10.1 17.4 15.7 2.6 5.9 18.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 -136.4 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 -111.7 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% -50.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   44.1 -6.9 19.1 -3.1 -9.2 8.7 -15.7 -15.7   Net working capital %   0.0% 3.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 -191 0 0 0 0 0 0   Added value / employee   44 -49 26 -37 -6 16 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   44 -49 26 -37 -6 16 0 0   EBIT / employee   44 -49 26 -37 -6 16 0 0   Net earnings / employee   44 -50 25 -43 -6 18 0 0